Fisher & Paykel Healthcare First Half Year Revenue Down

Industry News

& Articles

Fisher & Paykel Healthcare Revenue Down


First half-year revenue down 1 per cent to $900 million and net profit after tax down 2 per cent to $222 million; a solid result given extraordinarily high COVID induced hospitalisation and product demand, in prior comparable period.

  • 35 per cent gross margin improvement compared to the first half of 2021, attributable to partial reversal of higher freight costs incurred in the previous comparable period


  • Interim 17 cents dividend payable on 15 December, inclusive of full New Zealand imputation credit


  • $75.7 million R & D investment for 6 months to 30 September 2021 and $700 million for increased manufacturing and distribution capacity planned for coming 5 years


  • COVID uncertainty precludes FY22 quantitative earnings guidance; however medium term growth prospects remain solid.

Fisher & Paykel Healthcare Corporation Limited (‘FPH‘ or the ‘Company‘) is a New Zealand-based healthcare group that designs, manufactures and markets products for use in acute and chronic respiratory care, surgery and in the treatment of sleep apnoea. The Company’s products are sold in 120 countries.

FPH comprises 2 product groups; Hospital and Homecare. Hospital products are used in invasive ventilation and include humidification products essential in respiratory, acute and surgical care, including COVID patients. Homecare products include devices and systems to treat obstructive sleep apnoea in the home and comprise masks and flow generators as well as data recording and data management technologies.

FY22 half-year results to 30 September 2021

FPH announced a gratifying half-year result given the numbers were coming off the back of a period of extraordinary high demand for nasal high flow therapy and respiratory hospital products, arising from COVID-19 hospitalisation surges globally. Total operating revenue for the period was $900 million, a 1 per cent decline from the previous corresponding period. However, revenue in the previous financial year was up 56 per cent, boosted by a surge in demand for nasal high flow therapy products, in response to extremely high COVID induced hospitalisation rates globally. Net profit after tax was for the first half was $222 million, 2 per cent lower than the first half 2021 profit outcome.

Seventy-four per cent of total revenue or $670 million is generated by the Hospital product group. This component of the healthcare business provides the humidification products, hardware equipment and therapies essential for COVID patients requiring respiratory care. Two thirds of this $670 million is from the sale of consumables, while the remaining third relates to the sale of installed hospital hardware. It is the ongoing use of this installed base of hospital hardware that underpins future earnings growth. The other favourable longer-term impact of COVID is the heightened awareness and experience of more clinicians being exposed to the superior benefits of FPH’s therapies and products, compared to competitor offerings.

The remaining 26 per cent of total revenue is sourced through the Homecare product group.  These products are used in the treatment of obstructive sleep apnoea and respiratory support in the home.

Gross margin improved 1.35 per cent compared to the first half of 2021.  This improvement can be attributed to a partial reversal of higher freight costs incurred in the previous comparable period.  These costs however remain elevated, compared to pre-pandemic levels.

An interim dividend of 17 cents will be paid on 15 December and will carry a full New Zealand imputation credit. This is 6 per cent higher than the corresponding first half-year.

The Future

The Company continues to invest for the future. R & D investment in the 6 months period to September 2021 was $75.7 million. In addition, manufacturing and distribution capacity is being increased, with a $700 million capital expenditure program announced for the coming 5 years. This includes expanding the existing Auckland campus and acquiring land for a second New Zealand campus where R & D and manufacturing activities can be co-located. Longer term, three manufacturing plants will be built outside New Zealand. The first of these is under construction in Tijuana, Mexico.

FPH did not provide quantitative earnings and revenue guidance for the remainder of FY22, given the uncertainty around hospitalisations and government responses to COVID-19 case numbers. This was the same position adopted at the time of release of FY21 full year numbers.

The significant boost to hospital hardware sales revenue experienced in FY21 is unlikely to be repeated in FY22, as hospitals around the world now have sufficient hardware capacity to deal with current COVID levels. Hospital consumables revenue for the second half year is likely to be less than the second half of last financial year, as hospitalisations approach normality. Homecare product sales are dependent on patient diagnosis rates which are expected to be above FY21 rates in the second half year. This business segment accounts for just 26 per cent of total revenue.

The 6 per cent increase in the interim dividend and announced capital expenditure commitments of $700 million over 5 years, backed up by an elevated installed base of FPH hardware in hospitals around the world, is supportive of a positive long-term earnings prognosis for FPH.


Louis Mosmann

Louis Mosmann is a Private Wealth Client and Research Assistant at KOSEC- Kodari Securities. Louis covers macroeconomic events, global markets and ASX300 company announcements, allowing clients to make more informed investment decisions. Email Louis at

Comment on this company

Latest Stories

Iron Ore Prices Show Signs Of Rebound

Iron ore prices see a potential rebound in price……

Harvey Norman, Lockdown Restrictions Reduce Sales

Lockdown restrictions reduce sales by 8.8 per cent… …

NIB Holdings Limited Adds Kiwi Insurance And Telehealth Investment

NIB Holdings Limited (ASX:NHF) announces $4 million investment……

More for you

Northern Star Resources Limited Announces Kalgoorlie Power Plant Acquisition

Northern Star Resources Limited Announces Kalgoorlie Power Plant Acquisition……

Link Administration Holdings Limited Manages Strong Acquisition Interests Ahead Of 2H22 Results

Link Administration Holdings Limited Manages Strong Acquisition Interests Ahead Of 2H22 Results……

WiseTech Global Looks To Capitalise On Global Supply Chain Congestion

WiseTech Global Looks To Capitalise On Global Supply Chain Congestion……

Accent Group Limited Plots Ambitious Steps Towards Retail Expansion

Accent Group Limited Plots Ambitious Steps Towards Retail Expansion……

Sonic Healthcare Significantly High COVID-19 Test Volume

Significantly high COVID-19 test volume……

Aristocrat Leisure Rakes In Strong Earnings With FY21 Report

Aristocrat Leisure Limited has today published its FY21, highlighting……

KOSEC Terms & Conditions

Kodari Securities Pty Ltd (CAR 399556) trading as KOSEC is regulated by the Australian Securities and Investment Commission (ASIC). KOSEC is a financial services company and any information provided by its platforms, portals, reports and documents is protected by copyright. Any unauthorised production of this information is prohibited.
KOSEC reserves the right to change or remove any information provided on our website, reports or any documents including these terms and conditions at any time without notice. The change or modification to the terms and conditions will be effective immediately upon posting an updated version on our website, necessary platforms and documents. It is recommended that you review the information provided on our website, including these terms and conditions frequently for any changes.

KOSEC provides general advice only. The information provided is of a general nature only and does not take into account your individual objectives, financial situation or needs. It should not be used, relied upon, or treated as a substitute for specific professional advice. KOSEC recommends that you obtain your own independent professional advice before making any decision in relation to your particular requirements or circumstances. Please make sure you read our Financial Services Guide (FSG).

KOSEC does not guarantee any returns. Past performance of any product discussed is not indicative of future performance. (We urge that caution should be exercised in assessing past performance. All financial products are subject to market forces and unpredictable events that may adversely affect their future performance). Investing in the stock market can incur huge losses. Please also be aware that fees will incur on every transaction regardless of the performance of your investments or returns generated. Employees and or associates of KOSEC may hold one or more of the stocks, securities or investments reviewed by the company.

Your use of information from our website, reports, documents and from talking to our representatives/associates is at your risk. Under no circumstance should the investment be based solely on KOSEC information and general advice. You should seek professional financial planning advice.
KOSEC aims to maintain the accuracy of the data and information provided on this website, by using information prepared from a wide variety of sources, which KOSEC to the best of its knowledge and belief, considers accurate and does not make any representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability or availability of the information provided.

We may at times refer to third parties, which the details of these third parties have been provided solely for you to obtain further information about other relevant products and entities in the market. KOSEC has no control over the information third parties have, or the products or services offered, and therefore make no representations regarding the accuracy or suitability of such information, products or services. You are advised to make your own enquiries in relation to third parties. Our inclusion of any third party content is not an endorsement of that content or the third party.

As a client you will be charged a yearly service fee and a set brokerage fee per transaction. Your service fee will automatically renew at the end of your agreed 12 month period at the same rate advertised at the time. Your credit card or bank account will be charged for a further year following which will again auto renew until you cancel your yearly service fee. You can cancel the auto renewal at any time in advance of the renewal date by contacting us. KOSEC is aware of the need to ensure the security of your credit card details and our payment systems are compliant with the Payment Card Industry (PCI) Data Security Standard.

You consent to receiving email correspondence from KOSEC, as well as companies KOSEC has an association with. These emails will be sent by KOSEC and third party companies. You can opt out of receiving any category of emails at any time by contacting us. We may from time to time inform you of special offers, or even ask your opinion of the services we provide, but your involvement is optional. Should you request us to do so, we will archive your details.

Indemnity and Liability
You indemnify KOSEC from all claims or threatened claims, suits, demands, damages, costs as well as including legal costs incurred in dealing with any threatened claim, expenses made by any person or corporation against KOSEC and any other amounts which is caused by KOSEC providing information, execution and General Advice.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from a decision made by you on the basis of information obtained through the use of our portal, reports, documents or any General Advice given and any transaction taken place.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from delays in executing orders for the client and acknowledges KOSEC makes no guarantees about the time taken to execute an order on behalf of the client. You acknowledge that KOSEC relies on third parties in providing technology and release KOSEC from any harm, loss or damage you may suffer as a result of the failure of such information technology.

Cookies and Links
KOSEC website, and its portal uses cookies, which lets us identify your browser while you are using the site or our portal. Cookies do not identify you personally. They simply allow us to track your usage patterns. If you prefer not to receive cookies, you can configure your browser to reject them or to notify you when they are being used. The functionality of the KOSEC website may be impacted if you restrict the use of cookies.

Fill up the form below and we will get back to you as soon as possible.



KOSEC’s CEO, Michael Kodari’s new book, “Stock Market Success” valued at $39.95, available at Dymocks book stores with all the proceeds going to Dymocks Children’s Charities.


Latest TV Commercial